Summary

The global Peripheral vascular devices market is projected to reach USD 14.73 billion by 2029 from USD 11.43 billion in 2024, at a CAGR of 5.2% from 2024 to 2029. The market for peripheral vascular devices is sharply increasing in view of an increased prevalence of vascular diseases such as PAD and DVT. Other key drivers for this expansion are an aging population base, increased adoption of less-invasive procedures, and advancements in vascular technology in stents, angioplasty balloons, and catheters. Increased awareness about timely diagnosis and treatment options and supportive initiatives from the government further increase market demand. Improvement in global healthcare infrastructure and an increased number of specialized vascular clinics are adding to upward movement of the market.

“By type segment Angioplasty stent to account for the largest share during the forecast period”
The peripheral vascular devices market offers a higher share of stents used in the treatment of angioplasty mainly because stenting is vital in managing diseases such as PAD and CAD. Stents are designed to give long-term vessel support where by the lumen of the arteries needs to be maintained after having a balloon angioplasty. Unlike balloons or catheters, stents are not used only during procedures; they are a permanent solution to the narrowing of an artery, decreasing the chances of restenosis. Technological advancements employing drug-eluting stents (DES) and bioresorbable stents have enhanced the capability of stents by lowering complications and yielding a better prognosis in the long term, therefore making it highly popular.
Stents are also increasingly gaining popularity because they are minimally invasive, where time towards recovery by patients and even the number of days spent in hospitals can be reduced compared to EVAR, or Endovascular Aneurysm Repair traditional surgical methods. Moreover, since the incidence of cardiovascular diseases and pay policies on stent procedures are rapidly moving in a healthy and benign direction, stent stints take the lead. Moreover, given the large geriatric population, where revascularization needs keep soaring, angioplasty stents remain the market leader for peripheral vascular devices.

“APAC is estimated to register the highest CAGR during the forecast period.”
The Peripheral vascular devices market is divided into Five regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific region witnessed the highest CAGR during the forecast period. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. The increasing diabetic population and increase in obesity due to sedentary lifestyles reassesses also driving the growth of peripheral vascular devices in the APAC region.

The breakdown of the profile of primary participants in the peripheral vascular devices market:
• By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
• By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
• By Region: North America - 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%

List of Companies Profiled in the Report
 Boston scientific corporation(U.S)
 Medtronic (U.S)
 Abbott (U.S)
 Becton, Dickinson, and Company(U.S)
 Terumo Corporation (Japan)
 B. Braun Melsungen AG(Germany)
 Merit medical systems(U.S)
 Penumbra, inc.(U.S)
 Koninklijke Philips N.V..(Japan)


Research Coverage
This report studies the Peripheral vascular devices market based on type and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total Peripheral vascular devices market. The report forecasts the revenue of the market segments to five major regions.
Reasons to Buy the Report
This report also includes.
• Analysis of key drivers (technological advancements), restraints (Cost of the system), challenges (regulatory policies), and opportunities (Increase in minimally invasive procedures) contributing to the growth of the Peripheral vascular devices market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Peripheral vascular devices market.
• Market Development: Comprehensive information on the lucrative emerging markets type and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, and investments in the Peripheral vascular devices market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Peripheral vascular devices market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 MARKET SCOPE 29
1.3.1 MARKET SEGMENTATION 29
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 LIMITATIONS 31
1.5 MARKET STAKEHOLDERS 31
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Key industry insights 37
2.2 MARKET SIZE ESTIMATION 38
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 43
2.4 MARKET SHARE ANALYSIS 44
2.5 STUDY ASSUMPTIONS 44
2.6 RISK ASSESSMENT 44
2.7 RESEARCH LIMITATIONS 45
2.7.1 METHODOLOGY-RELATED LIMITATIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 PERIPHERAL VASCULAR DEVICES MARKET OVERVIEW 51
4.2 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE AND COUNTRY (2023) 52
4.3 PERIPHERAL VASCULAR DEVICES MARKET: GEOGRAPHIC SNAPSHOT 52

5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
5.2.1 DRIVERS 54
5.2.1.1 Rapid growth in geriatric population and subsequent increase in disease prevalence 54
5.2.1.2 Favorable reimbursement scenario for procedures 54
5.2.1.3 Increased prevalence of diabetes 55
5.2.1.4 Rising rate of tobacco consumption 56
5.2.1.5 Growing incidence of obesity 56
5.2.2 OPPORTUNITIES 57
5.2.2.1 High growth potential in emerging markets 57
5.2.3 CHALLENGES 58
5.2.3.1 Availability of alternative treatments 58
5.2.3.2 Dearth of skilled professionals with expertise in peripheral vascular devices 58
5.2.3.3 Product failures and recalls 58
5.3 INDUSTRY TRENDS 59
5.4 ECOSYSTEM ANALYSIS 59
5.5 VALUE CHAIN ANALYSIS 60
5.6 SUPPLY CHAIN ANALYSIS 61
5.7 PORTER’S FIVE FORCE ANALYSIS 62
5.7.1 THREAT OF NEW ENTRANTS 63
5.7.2 THREAT OF SUBSTITUTES 63
5.7.3 BARGAINING POWER OF SUPPLIERS 63
5.7.4 BARGAINING POWER OF BUYERS 63
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 64
5.8.1 KEY STAKEHOLDERS 64
5.8.2 BUYING CRITERIA 65
5.9 TECHNOLOGY ANALYSIS 66
5.9.1 KEY TECHNOLOGIES 66
5.9.1.1 Drug-eluting stents 66
5.9.1.2 Atherectomy devices 66
5.9.2 COMPLEMENTARY TECHNOLOGIES 66
5.9.2.1 Intravascular ultrasound 66
5.9.2.2 Optical coherence tomography 66
5.9.3 ADJACENT TECHNOLOGIES 66
5.9.3.1 Remote patient monitoring 66

5.10 REGULATORY LANDSCAPE 67
5.10.1 REGULATORY ANALYSIS 67
5.10.1.1 North America 67
5.10.1.1.1 US 67
5.10.1.1.2 Canada 67
5.10.1.2 Europe 68
5.10.1.3 Asia Pacific 68
5.10.1.3.1 Japan 68
5.10.1.3.2 China 68
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
5.11 TRADE ANALYSIS 71
5.11.1 IMPORT DATA 72
5.11.2 EXPORT DATA 73
5.12 PRICING ANALYSIS 73
5.12.1 AVERAGE SELLING PRICE TREND, BY REGION 74
5.12.2 AVERAGE SELLING PRICE, BY KEY PLAYERS 74
5.13 REIMBURSEMENT ANALYSIS 75
5.14 PATENT ANALYSIS 78
5.14.1 PATENT PUBLICATION TRENDS 78
5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 79
5.15 KEY CONFERENCES AND EVENTS, 2024–2025 80
5.16 CASE STUDIES 81
5.16.1 CASE STUDY 1: DRUG-COATED BALLOON HELPING IN REDUCING RESTENOSIS 81
5.16.2 CASE STUDY 2: IMPROVED OUTCOMES WITH TERUMO’S MISAGO STENT 81
5.17 UNMET NEEDS AND END-USER EXPECTATIONS 82
5.17.1 UNMET NEEDS 82
5.17.2 END-USER EXPECTATIONS 82
5.18 INVESTMENT & FUNDING SCENARIO 83
5.19 IMPACT OF AI ON PERIPHERAL VASCULAR DEVICES MARKET 84
6 PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 86
6.1 INTRODUCTION 87
7 ANGIOPLASTY STENTS MARKET, BY TYPE 88
7.1 INTRODUCTION 89
7.2 DRUG-ELUTING STENTS 91
7.2.1 DRUG-ELUTING STENTS TO WITNESS HIGHER ADOPTION 91
7.3 BARE-METAL STENTS 93
7.3.1 BARE-METAL STENTS, BY DELIVERY PLATFORM 95
7.3.1.1 Balloon-expandable stents 95
7.3.1.1.1 Better radial strength and ease of deployment to drive usage 95
7.3.1.2 Self-expandable stents 96
7.3.1.2.1 Flexibility, tolerance, and support for vessel movement and compression to propel market 96
8 ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY TYPE 98
8.1 INTRODUCTION 99
8.2 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS 100
8.2.1 RISING PREVALENCE AND NEED FOR TREATMENT TO DRIVE MARKET 100
8.3 THORACIC AORTIC ANEURYSM STENT GRAFTS 102
8.3.1 INCREASING INCIDENCE OF THORACIC AORTIC ANEURYSMS TO PROPEL ADOPTION 102
9 CATHETERS MARKET, BY TYPE 103
9.1 INTRODUCTION 104
9.2 ANGIOGRAPHY CATHETERS 105
9.2.1 ANGIOGRAPHY CATHETERS TO DOMINATE CATHETERS MARKET 105
9.3 GUIDING CATHETERS 107
9.3.1 GROWING NUMBER OF TARGET PROCEDURES TO DRIVE MARKET 107
9.4 IVUS/OCT CATHETERS 108
9.4.1 IVUS/OCT CATHETERS SEGMENT TO REGISTER HIGHEST GROWTH 108
10 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE 110
10.1 INTRODUCTION 111
10.2 RETRIEVABLE FILTERS 113
10.2.1 RETRIEVABLE FILTERS SEGMENT TO REGISTER HIGHER GROWTH 113
10.3 PERMANENT FILTERS 114
10.3.1 RISKS ASSOCIATED WITH PERMANENT FILTERS TO HAMPER SALES 114
11 ANGIOPLASTY BALLOONS MARKET, BY TYPE 115
11.1 INTRODUCTION 116
11.2 OLD/NORMAL BALLOONS 117
11.2.1 OLD/NORMAL BALLOONS TO DOMINATE ANGIOPLASTY BALLOONS MARKET 117
11.3 DRUG-ELUTING BALLOONS 119
11.3.1 DRUG-ELUTING BALLOONS TO WITNESS HIGHEST GROWTH 119
11.4 CUTTING & SCORING BALLOONS 121
11.4.1 PREFERENCE FOR MEDICATION AS PRIMARY TREATMENT FOR ATHEROSCLEROSIS TO RESTRAIN ADOPTION 121

12 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 123
12.1 INTRODUCTION 124
12.2 ATHERECTOMY DEVICES 126
12.2.1 INCREASING INCIDENCE OF ATHEROSCLEROSIS TO DRIVE MARKET 126
12.3 THROMBECTOMY DEVICES 127
12.3.1 GROWING DVT INCIDENCE TO DRIVE ADOPTION OF THROMBECTOMY DEVICES 127
13 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 129
13.1 INTRODUCTION 130
13.2 EMBOLIC PROTECTION DEVICES 130
13.2.1 INVESTMENTS IN TECHNOLOGICAL ADVANCEMENTS AND GROWING REGULATORY APPROVALS TO DRIVE MARKET 130
13.3 CHRONIC TOTAL OCCLUSION DEVICES 132
13.3.1 RISING SUPPORT FOR DEVICE DEVELOPMENT TO DRIVE MARKET 132
14 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE 134
14.1 INTRODUCTION 135
14.2 GUIDEWIRES 137
14.2.1 GUIDEWIRES TO HOLD LARGEST MARKET SHARE 137
14.3 VASCULAR CLOSURE DEVICES 138
14.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 138
14.4 INTRODUCER SHEATHS 140
14.4.1 POTENTIAL FOR REDUCING ARTERIAL DAMAGE TO DRIVE ADOPTION 140
14.5 BALLOON INFLATION DEVICES 141
14.5.1 INTEGRATED TECHNOLOGIES AND RISING NUMBER OF TARGET PROCEDURES TO PROPEL ADOPTION 141
15 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION 142
15.1 INTRODUCTION 143
15.2 NORTH AMERICA 144
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 145
15.2.2 US 148
15.2.2.1 Favorable reimbursement scenario to contribute to growth 148
15.2.3 CANADA 152
15.2.3.1 Increasing cases of chronic conditions to fuel market 152
15.3 EUROPE 155
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 155
15.3.2 GERMANY 159
15.3.2.1 Statutory health insurance policy to support growth 159
15.3.3 FRANCE 162
15.3.3.1 Growing geriatric population to drive market 162

15.3.4 UK 166
15.3.4.1 Increasing volume of coronary angioplasty procedures to sustain growth 166
15.3.5 SPAIN 169
15.3.5.1 Growing cases of diabetes and obesity to boost market 169
15.3.6 ITALY 173
15.3.6.1 Increasing prevalence of atherosclerotic cardiovascular disease to spur growth 173
15.3.7 REST OF EUROPE 176
15.4 ASIA PACIFIC 180
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 180
15.4.2 JAPAN 185
15.4.2.1 Large geriatric population to ensure sustained demand 185
15.4.3 CHINA 188
15.4.3.1 Growing incidence of lifestyle diseases to fuel market 188
15.4.4 INDIA 191
15.4.4.1 Rising prevalence of target diseases and growing healthcare expenditure to propel market 191
15.4.5 AUSTRALIA 195
15.4.5.1 High prevalence of cardiovascular and peripheral artery diseases to drive market 195
15.4.6 SOUTH KOREA 198
15.4.6.1 Rising rates of chronic diseases to boost market 198
15.4.7 REST OF ASIA PACIFIC 202
15.5 LATIN AMERICA 205
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 205
15.5.2 BRAZIL 208
15.5.2.1 Rising healthcare expenditure to aid growth 208
15.5.3 MEXICO 212
15.5.3.1 Increasing prevalence of cardiovascular diseases to spur growth 212
15.5.4 COLOMBIA 215
15.5.4.1 Growing incidence of peripheral artery diseases to expedite growth 215
15.5.5 ARGENTINA 218
15.5.5.1 Increasing prevalence of peripheral artery diseases to support market growth 218
15.5.6 REST OF LATIN AMERICA 221
15.6 MIDDLE EAST & AFRICA 224
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 225
15.6.2 GCC COUNTRIES 228
15.6.2.1 Rising cases of hypertension and associated cardiovascular diseases to drive market 228
15.6.3 REST OF MIDDLE EAST & AFRICA 231

16 COMPETITIVE LANDSCAPE 235
16.1 INTRODUCTION 235
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 235
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 235
16.3 REVENUE ANALYSIS 236
16.4 MARKET SHARE ANALYSIS 237
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 239
16.5.1 STARS 239
16.5.2 EMERGING LEADERS 239
16.5.3 PERVASIVE PLAYERS 239
16.5.4 PARTICIPANTS 239
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 241
16.5.5.1 Company footprint 241
16.5.5.2 Type footprint 242
16.5.5.3 Region footprint 243
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 244
16.6.1 PROGRESSIVE COMPANIES 244
16.6.2 DYNAMIC COMPANIES 244
16.6.3 RESPONSIVE COMPANIES 244
16.6.4 STARTING BLOCKS 244
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 246
16.7 BRAND/PRODUCT COMPARISON 247
16.8 COMPANY VALUATION AND FINANCIAL METRICS 248
16.8.1 FINANCIAL METRICS 248
16.8.2 COMPANY VALUATION 248
16.9 COMPETITIVE SCENARIO 249
16.9.1 PRODUCT LAUNCHES AND APPROVALS 249
16.9.2 DEALS 250
17 COMPANY PROFILES 252
17.1 KEY PLAYERS 252
17.1.1 BOSTON SCIENTIFIC CORPORATION 252
17.1.1.1 Business overview 252
17.1.1.2 Products offered 253
17.1.1.3 Recent developments 255
17.1.1.3.1 Product approvals 255
17.1.1.3.2 Deals 256
17.1.1.3.3 Other developments 256
17.1.1.4 MnM view 257
17.1.1.4.1 Right to win 257
17.1.1.4.2 Strategic choices 257
17.1.1.4.3 Weaknesses and competitive threats 257
17.1.2 MEDTRONIC 258
17.1.2.1 Business overview 258
17.1.2.2 Products offered 259
17.1.2.3 Recent developments 261
17.1.2.3.1 Product approvals 261
17.1.2.3.2 Deals 262
17.1.2.4 MnM view 262
17.1.2.4.1 Right to win 262
17.1.2.4.2 Strategic choices 262
17.1.2.4.3 Weaknesses and competitive threats 262
17.1.3 ABBOTT 263
17.1.3.1 Business overview 263
17.1.3.2 Products offered 264
17.1.3.3 Recent developments 266
17.1.3.3.1 Product launches 266
17.1.3.3.2 Deals 266
17.1.3.4 MnM view 266
17.1.3.4.1 Right to win 266
17.1.3.4.2 Strategic choices made 266
17.1.3.4.3 Weaknesses and competitive threats 267
17.1.4 BECTON, DICKINSON AND COMPANY 268
17.1.4.1 Business overview 268
17.1.4.2 Products offered 269
17.1.4.3 Recent developments 271
17.1.4.3.1 Product launches and approvals 271
17.1.4.3.2 Deals 272
17.1.4.3.3 Other developments 272
17.1.4.4 MnM view 273
17.1.4.4.1 Right to win 273
17.1.4.4.2 Strategic choices 273
17.1.4.4.3 Weaknesses and competitive threats 273
17.1.5 TERUMO CORPORATION 274
17.1.5.1 Business overview 274
17.1.5.2 Products offered 275
17.1.5.3 Recent developments 276
17.1.5.3.1 Product launches 276
17.1.5.4 MnM view 277
17.1.5.4.1 Right to win 277
17.1.5.4.2 Strategic choices 277
17.1.5.4.3 Weaknesses and competitive threats 277

17.1.6 B. BRAUN SE 278
17.1.6.1 Business overview 278
17.1.6.2 Products offered 279
17.1.7 MERIT MEDICAL SYSTEMS 281
17.1.7.1 Business overview 281
17.1.7.2 Products offered 282
17.1.7.3 Recent developments 283
17.1.7.3.1 Product launches 283
17.1.8 PENUMBRA, INC. 284
17.1.8.1 Business overview 284
17.1.8.2 Products offered 285
17.1.8.3 Recent developments 286
17.1.8.3.1 Product launches and approvals 286
17.1.9 KONINKLIJKE PHILIPS NV 287
17.1.9.1 Business overview 287
17.1.9.2 Products offered 288
17.1.9.3 Recent developments 289
17.1.9.3.1 Product approvals 289
17.1.9.3.2 Deals 289
17.1.10 STRYKER 290
17.1.10.1 Business overview 290
17.1.10.2 Products offered 291
17.1.11 CORDIS 293
17.1.11.1 Business overview 293
17.1.11.2 Products offered 293
17.1.11.3 Recent developments 295
17.1.11.3.1 Product approvals 295
17.1.11.3.2 Other developments 295
17.1.12 COOK 296
17.1.12.1 Business overview 296
17.1.12.2 Products offered 296
17.1.12.3 Recent developments 298
17.1.12.3.1 Deals 298
17.1.13 W. L. GORE & ASSOCIATES, INC. 299
17.1.13.1 Business overview 299
17.1.13.2 Products offered 299
17.1.13.3 Recent developments 301
17.1.13.3.1 Product approvals 301
17.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD. 302
17.1.14.1 Business overview 302
17.1.14.2 Products offered 302

17.1.15 IVASCULAR 303
17.1.15.1 Business overview 303
17.1.15.2 Products offered 303
17.1.16 BIOTRONIK 304
17.1.16.1 Business overview 304
17.1.16.2 Products offered 304
17.1.16.3 Recent developments 305
17.1.16.3.1 Product launches 305
17.1.17 ENDOLOGIX 306
17.1.17.1 Business overview 306
17.1.17.2 Products offered 306
17.1.18 ENDOCOR GMBH & CO., KG 307
17.1.18.1 Business overview 307
17.1.18.2 Products offered 307
17.2 OTHER PLAYERS 308
17.2.1 MERIL LIFE SCIENCES PVT. LTD. 308
17.2.2 ALVIMEDICA 309
17.2.3 CARDIONOVUM GMBH 310
17.2.4 SMT 310
17.2.5 MEDINOL 311
17.2.6 ANDRAMED GMBH 311
17.2.7 REX MEDICAL 312
17.2.8 QMD INC. 312
17.2.9 BROSMED MEDICAL CO., LTD. 313
17.2.10 ELIXIR MEDICAL 314
18 APPENDIX 315
18.1 DISCUSSION GUIDE 315
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 320
18.3 CUSTOMIZATION OPTIONS 322
18.4 RELATED REPORTS 322
18.5 AUTHOR DETAILS 323